Effect of metformin tablet on type 2 diabetes mellitus patients complicated with atherosclerosis and its influence on blood glucose level and clinical biochemical index
10.3760/cma.j.issn.1008-6706.2017.23.033
- VernacularTitle:二甲双胍治疗2型糖尿病合并动脉粥样硬化患者临床疗效及其对血糖水平和临床生化指标的影响
- Author:
Wenyi ZHENG
1
;
Zemin WANG
;
Minqiao ZHANG
Author Information
1. 315711,浙江省象山县第三人民医院药剂科
- Keywords:
Diabetes mellitus,Type 2;
Atherosclerosis;
Metformin;
Gliclazide sustained-release tablets;
Blood sugar
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(23):3647-3651
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of mefformin tablets in the treatment of type 2 diabetes mellitus(T2DM) with atherosclerosis.Methods A total of 84 T2DM patients with atherosclerosis were divided into control group and treatment group according to the random number table method,42 cases in each group.All patients were given diet control,health education and exercise,etc..The control group was treated with gliclazide sustained-release tablets.The treatment group was treated with mefformin and treated for 6 months.The levels of fasting blood glucose(FBG) and 2 h postprandial blood glucose(2hPBG) were measured before and 6 months after treatment.The levels of intima-media thickness (cIMT),leptin (LP),adiponectin (TC),chitinase-3-like protein-1 (YKL-40),triglyceride (TG),low density lipoprotein cholesterol (HDL-C) and high-density lipoprotein cholesterol (HDL-C) were measured.The adverse reactions were observed in the two groups.Results After treatment for 6 months,the levels of FBG and 2hPBG in the treatment group were (6.71 ±0.41) mmol/L and (8.82 ±0.61) mmol/L,respectively,which were significantly lower than those in the control group [(6.96 ± 0.48) mmol/L,(9.58 ± 0.57) mmol/L,t =2.56,5.89,P =0.01,0.00].The levels of cIMT,TC,TG and LDL-C in the treatment group were significantly lower than those in the control group at 6 months after treatment (t =5.36,6.46,9.10,2.31,P =0.00,0.00,0.00,0.02).After 6 months of treatment,the HDL-C level of the treatment group was significantly higher than that of the control group (t =2.84,P =0.00).After treatment for 6 months,HDL-C level in the two groups was significantly higher than before treatment,the other indicators in the two groups were significantly lower than before treatment (all P ＜ 0.05).There were no adverse reactions in the two groups during treatment.Conclusion Metformin in the treatment of T2DM patients with atherosclerosis has significant effect,it can improve blood glucose levels and the clinical and biochemical indicators,and it is safe.
